Anna-Karin Berger, Andreas Rieckmann, Krishan Nighah, Stefano Zanigni
{"title":"Psychometric assessment of a modified part I of the unified multiple system atrophy rating scale","authors":"Anna-Karin Berger, Andreas Rieckmann, Krishan Nighah, Stefano Zanigni","doi":"10.1016/j.prdoa.2026.100510","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Despite widespread use in MSA clinical trials, the UMSARS has recognized limitations in responsiveness.</div></div><div><h3>Objectives</h3><div>To evaluate the psychometric properties of a modified UMSARS Part I incorporating collapsed response categories (0 and 1) and excluding item 11 (sexual function).</div></div><div><h3>Methods</h3><div>Psychometric properties and responsiveness of the modified UMSARS Part I were assessed and compared with other UMSARS scores using data from a randomized, double-blind, placebo-controlled trial.</div></div><div><h3>Results</h3><div>For the mUMSARS Part I, internal consistency (Cronbach's alpha) was 0.80 at Week 48 and 0.76 at end-of-treatment, and test-retest reliability (intraclass correlation coefficient) was 0.61. Construct validity for mUMSARS Part I ranged from <em>r</em> = 0.51–0.72, comparable to the UMSARS Total score (<em>r</em> = 0.49–0.69) and higher than UMSARS Part I (<em>r</em> = 0.42–0.60). At Week 48, mUMSARS Part I effect sizes across global impression anchors were large in worsening groups (1.64–2.92) and lower in no-change groups (0.97–1.62).</div></div><div><h3>Conclusions</h3><div>The modified scale demonstrates acceptable psychometric properties, supporting its use in trials assessing progression of MSA. Both the original UMSARS Part I and mUMSARS Part I performed well across psychometric assessments; however, the mUMSARS Part I showed consistently stronger construct validity and greater responsiveness to change.</div></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"15 ","pages":"Article 100510"},"PeriodicalIF":2.7000,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Parkinsonism Related Disorders","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2590112526000903","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/10/13 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Despite widespread use in MSA clinical trials, the UMSARS has recognized limitations in responsiveness.
Objectives
To evaluate the psychometric properties of a modified UMSARS Part I incorporating collapsed response categories (0 and 1) and excluding item 11 (sexual function).
Methods
Psychometric properties and responsiveness of the modified UMSARS Part I were assessed and compared with other UMSARS scores using data from a randomized, double-blind, placebo-controlled trial.
Results
For the mUMSARS Part I, internal consistency (Cronbach's alpha) was 0.80 at Week 48 and 0.76 at end-of-treatment, and test-retest reliability (intraclass correlation coefficient) was 0.61. Construct validity for mUMSARS Part I ranged from r = 0.51–0.72, comparable to the UMSARS Total score (r = 0.49–0.69) and higher than UMSARS Part I (r = 0.42–0.60). At Week 48, mUMSARS Part I effect sizes across global impression anchors were large in worsening groups (1.64–2.92) and lower in no-change groups (0.97–1.62).
Conclusions
The modified scale demonstrates acceptable psychometric properties, supporting its use in trials assessing progression of MSA. Both the original UMSARS Part I and mUMSARS Part I performed well across psychometric assessments; however, the mUMSARS Part I showed consistently stronger construct validity and greater responsiveness to change.